Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
Liposomes useful for drug delivery to the brain
US9737528B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9737528-B2 |
| Application number | US-201615296536-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 18, 2016 |
| Priority date | May 3, 2004 |
| Publication date | Aug 22, 2017 |
| Grant date | Aug 22, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain.
First claim
Opening claim text (preview).
What is claimed is: 1. An injectable liquid pharmaceutical composition comprising irinotecan sucrose octasulfate encapsulated within liposomes comprising DSPC, cholesterol and PEG-DSPE in a molar ratio of 3:2:0.015, the liposomes having a diameter of 95-110 nm and encapsulating a total amount of irinotecan in 500-550 mg irinotecan hydrochloride per mmol of the total liposome phospholipids, and the pharmaceutical composition having a potency of 20-80 mg of total irinotecan per mL of the pharmaceutical composition.
Assignees
Inventors
Classifications
the tumour determinant being from breast cancer cell · CPC title
the liposome being modified on its surface by an antibody · CPC title
liposomes, polymersomes, e.g. immunoliposomes · CPC title
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title
Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9737528B2 cover?
- The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain.
- Who is the assignee on this patent?
- Ipsen Biopharm Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4745. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).